Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL).
Advertisement